For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 76,996 | |||
| General and administrative | 23,850 | |||
| Impairment charge | 3,175 | |||
| Total operating expenses | 104,021 | |||
| Loss from operations | -104,021 | |||
| Interest income | 3,964 | |||
| Interest expense | 1,602 | |||
| Other income (expense), net | -36 | |||
| Loss before income taxes | -101,695 | |||
| Income tax provision | 0 | |||
| Net loss | -101,695 | |||
| Basic EPS | -1.9 | |||
| Diluted EPS | -1.9 | |||
| Basic Average Shares | 53,658,399 | |||
| Diluted Average Shares | 53,658,399 | |||
ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC (ALXO)